Cargando…
Safety and Varicella Outcomes in In Utero–Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program
BACKGROUND: Infants exposed to varicella zoster virus (VZV) in utero ≤5 days before or ≤48 hours after delivery and preterm infants are at high risk for varicella complications. An expanded-access program assessed varicella outcomes after administration of varicella zoster immune globulin (human) (V...
Autores principales: | Duchon, Jennifer M, Levin, Myron J, Gershon, Anne A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495903/ https://www.ncbi.nlm.nih.gov/pubmed/31774916 http://dx.doi.org/10.1093/jpids/piz070 |
Ejemplares similares
-
Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program
por: Levin, Myron J., et al.
Publicado: (2019) -
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program
por: Gans, Hayley, et al.
Publicado: (2021) -
2479. Varicella Zoster Immune Globulin Is Effective up to 10 Days Following Varicella Exposure in Pregnant Women, Immunocompromised Patients, and Infants: Results From a Large, Open-Label Expanded-Access Program
por: Levin, Myron, et al.
Publicado: (2018) -
Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster
por: Gershon, Anne A, et al.
Publicado: (2021) -
Silent Reactivation of Varicella Zoster Virus in Pregnancy: Implications for Maintenance of Immunity to Varicella
por: Mourad, Mirella, et al.
Publicado: (2022)